Redeye updates its estimates ahead of the Q3 report (due 27 October) with a small downward adjustmen...
The gap-fill process will allow Biovica to secure a Medicare (CMS) code and a preliminary price as o...
Bolaget har spännande prospektering på gång, vilket vid ett lyckosamt utförande kan ge ett bra värde...
Redeye comments on today’s news from SDS, where the company announced the outcome of the directed sh...
Value accretive shift in strategy Directed share issue of SEK 150m Fair value range up to SEK 9-15 (...
Q3e sales SEK 49m, -14% y-o-y, +17% q-o-q; EBIT SEK -3m (-2m) Change of analyst: '23e-'25e sales dow...
Redeye is encouraged by the publication of the clinical results from a study at the University Child...
EcoRub meddelade nyligen att de lanserar färgade återvunna TPE-material och material för 3D-printing...
Redeye is once again positively surprised that Arise will see further revenue recognition and receiv...
The Norwegian competitor Q-FREE, listed on the Oslo stock exchange, has a bid placed on it by Junipe...
• Q3 report due 25 Oct • Q3'23e net sales SEK 167m, EBITA SEK 22m • Share trading at 6x Factset cons...
Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to ...
PolarCool meddelade idag den 26 september att bolaget har förlängt avtalet med HC Davos, vilket är e...
EcoRub genomför just nu bolagets företrädesemission där teckningstiden pågår fram tills den 11 oktob...
Redeye ups its near-term sales estimates for Ortoma following its USD8.
Redeye comments on W5’s announced acquisition of Box Modul which will add customized shelters to its...
Redeye considers the partnership with Elon Group AB (Elon) to be a strategically sound move that ali...
Biovica has signed its second direct commercial client bill agreement with a larger healthcare prov...
Redeye ser positivt på morgonens besked att Leqembi har godkänts i Japan och därmed att BioArctic få...
Redeye is favorable to the initiation of a new pilot with Bare Dermatology based in Texas.
